Drugs & Therapy Perspectives

, Volume 19, Issue 9, pp 4–6 | Cite as

Memantine: profile report

  • Hans Förstl
  • Anne-Sophie Rigaud
Drugs and Profile Reports


Dementia Linezolid Memantine Vascular Dementia Actinic Keratose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jarvis B, Figgitt DP. Memantine. Drugs and Aging 2003; 20(6): 465–76PubMedCrossRefGoogle Scholar
  2. 2.
    Förstl H. Memantine: a viewpoint. Drugs and Aging 2003; 20(6): 477CrossRefGoogle Scholar
  3. 3.
    Rigaud A-S. Memantine: a viewpoint. Drugs and Aging 2003; 20(6): 477–8CrossRefGoogle Scholar
  4. 4.
    Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999 Nov; 25: 341Google Scholar
  5. 5.
    Erkinjuntti T. Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs 1999 Jul; 12: 35–48CrossRefGoogle Scholar
  6. 6.
    Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry 1999; 14(1): 3–47PubMedCrossRefGoogle Scholar
  7. 7.
    Reisberg B, Doody R, Stöffler A, et al. A randomized, placebo-controlled study of memantine, an uncompetitive NMDA antagonist, in patients with moderate to severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41PubMedCrossRefGoogle Scholar
  8. 8.
    Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999 Feb; 14(2): 135–46PubMedCrossRefGoogle Scholar
  9. 9.
    Orgogozo J-M, Rigaud A-S, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002 Jul; 33(7): 1834–9PubMedCrossRefGoogle Scholar
  10. 10.
    Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002 Nov; 17(6): 297–30PubMedCrossRefGoogle Scholar
  11. 11.
    H. Lundbeck A/S. Summary of product characteristics. Ebixa (memantine hydrochloride). Valby, Denmark, 2002Google Scholar
  12. 12.
    Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine: results of a phase II double-blind study. Pharmacopsychiatry 1988 May; 21(3): 144–6PubMedCrossRefGoogle Scholar
  13. 13.
    Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 1991 Aug; 41(8): 773–80PubMedGoogle Scholar
  14. 14.
    Tempel D. Memantine in organic brain syndromes. Therapiewoche 1989; 39: 946–52Google Scholar
  15. 15.
    Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychol Psychiatr 1993; 6: 103–17Google Scholar
  16. 16.
    Rieke J, Glaser A. Efficacy and tolerability of memantine in patients with dementia [in German]. Med Welt 1996; 47(6): 251–4Google Scholar
  17. 17.
    Ruther E, Glaser A, Bleich S, et al. A prospective PMS study to validate the sensitivity for change of the D- scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000 May; 33(3): 103–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Hans Förstl
    • 1
  • Anne-Sophie Rigaud
    • 2
  1. 1.Department of Psychiatry and PsychotherapyTechnical University MunichMunichGermany
  2. 2.Hôpital Broca, CHU Cochin Port-RoyalUniversité René DescartesParisFrance

Personalised recommendations